Collectively, our findings revealed the role of dietary fructose in MASLD pathogenesis and identified the USP2-mediated C/EBPα/ 11β-HSD1 signaling as a potential target for the management of MASLD. The gene discussed is USP2; the disease is metabolic dysfunction-associated steatotic liver disease.